Magnetoresistance, specific heat and magnetocaloric effect of equiatomic rare-earth transition-metal magnesium compounds

We present a study of the magnetoresistance, the specific heat and the magnetocaloric effect of equiatomic $RET$Mg intermetallics with $RE = {\rm La}$, Eu, Gd, Yb and $T = {\rm Ag}$, Au and of GdAuIn. Depending on the composition these compounds are paramagnetic ($RE = {\rm La}$, Yb) or they order either ferro- or antiferromagnetically with transition temperatures ranging from about 13 to 81 K. All of them are metallic, but the resistivity varies over 3 orders of magnitude. The magnetic order causes a strong decrease of the resistivity and around the ordering temperature we find pronounced magnetoresistance effects. The magnetic ordering also leads to well-defined anomalies in the specific heat. An analysis of the entropy change leads to the conclusions that generally the magnetic transition can be described by an ordering of localized $S=7/2$ moments arising from the half-filled $4f^7$ shells of Eu$^{2+}$ or Gd$^{3+}$. However, for GdAgMg we find clear evidence for two phase transitions indicating that the magnetic ordering sets in partially below about 125 K and is completed via an almost first-order transition at 39 K. The magnetocaloric effect is weak for the antiferromagnets and rather pronounced for the ferromagnets for low magnetic fields around the zero-field Curie temperature.Comment: 12 pages, 7 figures include

Pyoderma gangrenosum – a review

Pyoderma gangrenosum (PG) is a rare noninfectious neutrophilic dermatosis. Clinically it starts with sterile pustules that rapidly progress and turn into painful ulcers of variable depth and size with undermined violaceous borders. The legs are most commonly affected but other parts of the skin and mucous membranes may also be involved. Course can be mild or malignant, chronic or relapsing with remarkable morbidity. In many cases PG is associated with an underlying disease, most commonly inflammatory bowel disease, rheumatic or haematological disease and malignancy. Diagnosis of PG is based on history of an underlying disease, typical clinical presentation, histopathology, and exclusion of other diseases that would lead to a similar appearance. The peak of incidence occurs between the ages of 20 to 50 years with women being more often affected than men. Aetiology has not been clearly determined yet. The treatment of PG is a challenge. Randomized, double-blinded prospective multicenter trials for PG are not available. The best documented treatments are systemic corticosteroids and ciclosporin A. Combinations of steroids with cytotoxic drugs are used in resistant cases. The combination of steroids with sulfa drugs or immunosuppressants has been used as steroid-sparing modalities. Anti-tumor necrosis alpha therapy in Crohn's disease showed a rapid response of PG. Skin transplants and the application of bioengineered skin is useful in selected cases as a complement to the immunosuppressive treatment. Topical therapy with modern wound dressings is useful to minimize pain and the risk of secondary infections. Despite recent advances in therapy, the prognosis of PG remains unpredictable